These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38352877)

  • 1. The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy.
    Wang D; Wang X; Zhang Y; Yu L; An J; Wang X; Huang Y; Han X
    Front Immunol; 2024; 15():1309509. PubMed ID: 38352877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
    Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
    Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.
    Yin P; Wang Y; Qiu Y; Hou L; Liu X; Qin J; Duan Y; Liu P; Qiu M; Li Q
    Int J Nanomedicine; 2012; 7():3961-9. PubMed ID: 22888239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
    Gou HF; Huang J; Shi HS; Chen XC; Wang YS
    PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
    Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
    Shen N; Yang C; Zhang X; Tang Z; Chen X
    Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
    Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
    J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation.
    Yu H; Tang Z; Li M; Song W; Zhang D; Zhang Y; Yang Y; Sun H; Deng M; Chen X
    J Biomed Nanotechnol; 2016 Jan; 12(1):69-78. PubMed ID: 27301173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
    Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
    Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
    Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
    Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin mediated down-regulation of α
    Javadi S; Rostamizadeh K; Hejazi J; Parsa M; Fathi M
    Phytother Res; 2018 Feb; 32(2):355-364. PubMed ID: 29168312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.